Jabil Inc vs Tilray Brands Inc — how do they compare? Jabil Inc trades at $368.56 (market cap $37.37B), while Tilray Brands Inc trades at $4.78 (market cap $649.42M). The key difference: Jabil Inc is far larger — about 57.5× Tilray Brands Inc's market cap, and Jabil Inc pays a 0.09% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| JBL | TLRY | |
|---|---|---|
Market Cap | $37.37B | $649.42M |
Sector | Technology | Health |
52-Week High | $385.50 | $21.00 |
52-Week Low | $192.49 | $3.88 |
Enterprise Value | $39.90B | $816.55M |
Dividend Yield | 0.09% | — |
Signals from Pluang's Aura AI — not financial advice
Jabil (JBL) trades at $366.10, up 8.75% in 24 hours, reflecting strong momentum driven by AI infrastructure demand. The stock shows bullish technical signals with a consensus price target of $448.29, indicating 22% upside. Recent earnings beats and projected AI revenue growth to over $20 billion by fiscal 2027 (UBS, August 11, 2026) support optimism, though high P/E of 44.63 and thin net margins near 2.6% warrant caution.
Outlook is positive with AI-driven expansion, but risks include valuation sensitivity and competitive pressures. Investment appeal hinges on execution of growth forecasts, while volatility may arise from macroeconomic shifts or supply chain disruptions.
TLRY trades at $4.71, up 6.56% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $821M in 2025, yet the company posted a net loss of -$2.19B, reflecting profitability challenges. Recent news highlights growth initiatives, including a partnership with Wolverhampton Wanderers and a new THC pouch launch. The stock remains volatile, with a low P/S of 0.58 and P/B of 0.4, suggesting potential undervaluation amid ongoing losses.
Outlook is cautious; TLRY's path to profitability hinges on revenue growth and cost management. Risks include persistent losses, high debt, and regulatory uncertainty. Analyst consensus is mixed, with 25% buy ratings but 65% hold, indicating skepticism. Investors should weigh growth potential against financial instability and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →